Status:
RECRUITING
Prevalence of Mast Cell Activation Syndrome in Patients With EDS With Digestive Disorders
Lead Sponsor:
Lille Catholic University
Conditions:
Ehlers Danlos Hypermobile Syndrome
Eligibility:
All Genders
14+ years
Brief Summary
The aim of the study is to confirm the association between hypermobile Ehlers Danlos syndrome (hEDS) and mast cell activation syndrome (MCAS) in patients with digestive disorders managed in allergolog...
Eligibility Criteria
Inclusion
- with hypermobile Ehlers Danlos syndrome
- with digestive disorders
- 14 years of age or older (minimum age for the MOS-SF 36 questionnaire)
- able to answer the questionnaires
- whose participation in a day hospital at Saint Vincent de Paul dedicated to the assessment of "functional digestive pain" is planned
- who do not object to the use of their health data for research purposes
- Additional criteria for minors :
- \- No objection to the use of health data for research purposes by parents/guardians
Exclusion
- under guardianship or curatorship
- having taken a long-term high-dose antihistamine treatment (H1 or H2) during the last two months, according to the following thresholds :
- Desloratadine (\>5 mg/jour)
- Bilastine (\>20 mg/jour)
- Cetirizine (\>20 mg/jour)
- Ebastine (\>10 mg/jour)
- Fexofenadine (\>150 mg/jour)
- Levocetirizine (\>5 mg/jour)
- Loratadine (\>10 mg/jour)
- Exocetiridine (5 mg/jour)
- Mizolastine (\>10 mg/jour)
- Rupatadine (\>10 mg/jour)
- Polaramine (\>10 mg/jour)
- Oxomemazine (\>2 mg/jour)
- Hydroxyzine (\>25 mg/jour)
- Doxylamine (\>15 mg/jour)
- Cimetidine (\>200 mg/jour)
- Patients deprived of liberty, pregnant or nursing women
Key Trial Info
Start Date :
September 28 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05382169
Start Date
September 28 2022
End Date
March 1 2026
Last Update
January 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint-Vincent-de-Paul hospital
Lille, Nord, France, 59020